| 5.17 -0.23 (-4.26%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.08 | 1-year : | 8.27 |
| Resists | First : | 6.06 | Second : | 7.08 |
| Pivot price | 4.71 |
|||
| Supports | First : | 4.76 | Second : | 3.96 |
| MAs | MA(5) : | 5.37 |
MA(20) : | 4.63 |
| MA(100) : | 6.09 |
MA(250) : | 6.68 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 65.5 |
D(3) : | 72.7 |
| RSI | RSI(14): 55.1 |
|||
| 52-week | High : | 12.35 | Low : | 3.78 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RXRX ] has closed below upper band by 27.6%. Bollinger Bands are 20% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.42 - 5.45 | 5.45 - 5.47 |
| Low: | 5.05 - 5.09 | 5.09 - 5.12 |
| Close: | 5.12 - 5.18 | 5.18 - 5.22 |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Wed, 11 Jun 2025
Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable (NASDAQ:RXRX) - Seeking Alpha
Tue, 10 Jun 2025
Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI - Insider Monkey
Tue, 10 Jun 2025
Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening? - Benzinga
Tue, 10 Jun 2025
Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky (RXRX) - Seeking Alpha
Tue, 10 Jun 2025
Recursion Pharma to reduce workforce by 20% (RXRX:NASDAQ) - Seeking Alpha
Tue, 10 Jun 2025
Recursion Pharmaceuticals Stock (RXRX): AI Breakthrough for Drug Development - Value The Markets
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 400 (M) |
| Held by Insiders | 3.886e+008 (%) |
| Held by Institutions | 5 (%) |
| Shares Short | 94,520 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.2558e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 297.8 % |
| Return on Equity (ttm) | -38.6 % |
| Qtrly Rev. Growth | 5.979e+007 % |
| Gross Profit (p.s.) | 8.31 |
| Sales Per Share | -103.74 |
| EBITDA (p.s.) | -4.48928e+008 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -389 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 1.86 |
| Dividend | 0 |
| Forward Dividend | 1.0422e+008 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|